144
Views
6
CrossRef citations to date
0
Altmetric
Review

Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

ORCID Icon, ORCID Icon & ORCID Icon
Pages 69-75 | Published online: 03 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione & Giuseppe Curigliano. (2022) Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opinion on Investigational Drugs 31:6, pages 499-513.
Read now

Articles from other publishers (5)

Chi Xu, Yahui Wang, Yuanyuan Hong, Ru Yao, Lijia Wu, Xi Shen, Yang Qu, Zhuo Zhang, Wei Zhu, Ying Yang, Weizhi Chen, Yidong Zhou & Zhiyong Liang. (2023) Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment. Breast Cancer Research and Treatment 199:3, pages 603-615.
Crossref
Suman Kumar Ray & Sukhes Mukherjee. (2023) Altering Landscape of Cancer Vaccines: Unique Platforms, Research on Therapeutic Applications and Recent Patents. Recent Patents on Anti-Cancer Drug Discovery 18:2, pages 133-146.
Crossref
Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begoña Bermejo & Juan Miguel Cejalvo. (2022) Immunological Landscape of HER-2 Positive Breast Cancer. Cancers 14:13, pages 3167.
Crossref
Ban Qi Tay, Quentin Wright, Rahul Ladwa, Christopher Perry, Graham Leggatt, Fiona Simpson, James W. Wells, Benedict J. Panizza, Ian H. Frazer & Jazmina L. G. Cruz. (2021) Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions. Vaccines 9:5, pages 535.
Crossref
Paolo Tarantino, Stefania Morganti & Giuseppe Curigliano. (2021) Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy.
Crossref